BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6629296)

  • 21. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A trial of the use of the hypolipidemic preparation Lipanor (ciprofibrate) in patients with primary hyperlipidemia].
    Kukharchuk VV; Rozhkova TA; Kotova LA; Tvorogova MG; Semenova OA
    Ter Arkh; 1996; 68(6):58-61. PubMed ID: 8771689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
    Vorberg G; Ziegler WJ
    Arzneimittelforschung; 1980; 30(11b):2068-72. PubMed ID: 7194062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories.
    Milionis HJ; Elisaf MS
    Curr Med Res Opin; 2000; 16(3):164-70. PubMed ID: 11191005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapy with fibrates and vitamin D metabolism].
    Wilczek H; Sobra J; Ceska R; Justová V; Procházková R; Kvasilová M; Jůzová Z
    Cas Lek Cesk; 1993 Oct; 132(20):630-2. PubMed ID: 8269466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutic effects of bezafibrate in hyperlipidemia].
    Kunesová M; Honková M; Zeman M; Mares P; Skorepa J
    Cas Lek Cesk; 1983 May; 122(20):628-31. PubMed ID: 6342789
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of sodium valproate monotherapy on serum uric acid concentrations in ambulatory epileptic children: a prospective long-term study.
    Attilakos A; Voudris KA; Garoufi A; Mastroyianni S; Dimou S; Prassouli A; Katsarou E
    Eur J Paediatr Neurol; 2006; 10(5-6):237-40. PubMed ID: 17035050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the hypolipaemic activity of etofylline clofibrate, a new ester of etofylline and clofibric acid, and comparison with effects of known hypolipaemic agents.
    Davies JE; Kellett DN
    Arzneimittelforschung; 1980; 30(11b):2035-7. PubMed ID: 7194055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
    Füsgen I; Summa JD
    Med Klin; 1980 Nov; 75(23):823-5. PubMed ID: 7442597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Problems of long-term treatment of hyperlipoproteinemia with clofibrinic acid].
    Hanefeld M; Schulze J; Fritz T; Kemmer C
    Z Gesamte Inn Med; 1973 May; 28(10):Suppl 10:160 c. PubMed ID: 4200340
    [No Abstract]   [Full Text] [Related]  

  • 31. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
    Melenovsky V; Stulc T; Kozich V; Grauova B; Krijt J; Wichterle D; Haas T; Malik J; Hradec J; Ceska R
    Am Heart J; 2003 Jul; 146(1):110. PubMed ID: 12851616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical experimentation of clofibride. Apropos of 40 cases].
    Warembourg H; Jaillard J
    Lille Med; 1973 Dec; 18(10 Suppl 5):suppl 5:1292-6. PubMed ID: 4802928
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-term treatment of hyperlipidemic patients with clofibrate.
    Berkowitz D
    JAMA; 1971 Nov; 218(7):1002-5. PubMed ID: 5000568
    [No Abstract]   [Full Text] [Related]  

  • 35. The metabolic spectrum of halofenate.
    Ryan JR
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):239-43. PubMed ID: 51838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic therapy for the hyperlipidemic patient.
    Hunninghake DB
    Am J Med; 1983 May; 74(5A):19-22. PubMed ID: 6846378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Halofenate: an effective hypolipemia- and hypouricemia-inducing drug.
    Aronow WS; Vangrow JS; Nelson WH; Pagano J; Papageorge's NP; Khursheed M; Harding PR; Khemka M
    Curr Ther Res Clin Exp; 1973 Dec; 15(12):902-6. PubMed ID: 4203573
    [No Abstract]   [Full Text] [Related]  

  • 38. Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children.
    Tumgor G; Arikan C; Kilic M; Aydogdu S
    Pediatr Transplant; 2006 Sep; 10(6):665-8. PubMed ID: 16911488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The effect of hypolipemic treatment on the pharmacokinetics of propranolol].
    Sterna R
    Ann Acad Med Stetin; 1997; 43():67-77. PubMed ID: 9471924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
    Ditschuneit HH; Hutt V; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1980; 30(11b):2063-7. PubMed ID: 7194061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.